Legend Biotech's Financial Performance
Legend Biotech Corp has demonstrated strong financial results in their Q2 2024 earnings call, showcasing significant revenue growth and strategic advancements in CAR-T cell therapy. Notably, net trade sales reached $186 million, reflecting a 50% year-over-year increase and an 18.5% growth quarter-over-quarter. Total revenues were reported at $187 million, with collaboration revenue from the sale of CARVYKTI contributing $93 million.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
